广州白云山明兴制药取得一种药物不良反应痕迹管理方法与系统专利

金融界
15 Feb

金融界2025年2月15日消息,国家知识产权局信息显示,广州白云山明兴制药有限公司取得一项名为“一种药物不良反应痕迹管理方法与系统”的专利,授权公告号 CN 118280602 B,申请日期为2024年4月。

天眼查资料显示,广州白云山明兴制药有限公司,成立于1962年,位于广州市,是一家以从事医药制造业为主的企业。企业注册资本4609.1897万人民币,实缴资本4609.1897万人民币。通过天眼查大数据分析,广州白云山明兴制药有限公司共对外投资了3家企业,参与招投标项目3364次,知识产权方面有商标信息88条,专利信息109条,此外企业还拥有行政许可469个。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10